LISCure Biosciences

About:

LISCure Biosciences is a biotech company that researches and develops bacteria-mediated immunotherapy.

Top Investors: KOREA INVESTMENT & SECURITIES, KDB Capital, KB Securities, Industrial Bank of Korea, Shinhan Investment

Description:

LISCure Biosciences is a developer of bacteria-mediated immunotherapy designed to treat tumors as well as degenerative neurological, autoimmune and metabolic diseases. The company currently has seven pipelines of medicine and two pipelines of health-functioning food and is considering the introduction of two more pipes.

Total Funding Amount:

17.5B KRW

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Seoul, Seoul-t'ukpyolsi, South Korea

Founded Date:

2018-12-01

Contact Email:

admin(AT)liscure.bio

Founders:

Hwaseop Chin, Junyoung Kil

Number of Employees:

1-10

Last Funding Date:

2020-12-31

IPO Status:

Private

Industries: